At a glance
- Originator Takeda
- Class Irritable bowel syndrome therapies; Naphthyridines
- Mechanism of Action Neurokinin 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Irritable bowel syndrome; Major depressive disorder; Pollakisuria; Urinary incontinence
Most Recent Events
- 03 Feb 2017 Discontinued - Phase-I for Urinary incontinence in Japan (PO)
- 07 Nov 2003 Discontinued - Phase-II for Depression in USA (unspecified route)
- 07 Nov 2003 Discontinued - Phase-II for Irritable bowel syndrome in USA (unspecified route)